Clinical efficacy of low energy cardioversion in automatic implantable cardioverter defibrillator patients

K. McVeigh, Morton Maimon Mower, S. Nisam, L. Voshage

Research output: Contribution to journalArticle

Abstract

The inclusion of low energy cardioversion capability into modern implantable antiarrhythmic devices, although an appealing idea, is nevertheless unproven with regard to its potential benefits. Moreover, since occasional reports have surfaced suggesting that ineffective application of low energy shocks may prejudice subsequent arrhythmia reversion, we examined the effectiveness and risks of this feature in a large series of patients performed as part of a US Food and Drug Administration clinical trial performed under an investigational device exemption. A total of 813 induced monomorphic ventricular tachycardias were studied in 244 patients. We found that many of the arrhythmias could be reverted to sinus rhythm with small amounts of energy. Cardioversion energy was ≤ 6 joules (J) for 84 (53.2%) and ≤ 14 joules in 105 (66.4%) of the 158 patients tested at implant and subsequently remained unchanged through > 4 months follow up. The incidence of noncardioversion, acceleration or both occurred in 12.7%, 5.7%, and 13.1%, respectively on a per patient basis. On a per episode basis, nonconversion occurred in 51 (6.3%) and acceleration in 61 (7.5%) of the 813 inductions. There was no correlation between the occurrence of nonconversions and accelerations. The devices were allowed to recycle in the event the arrhythmia was not reverted. The subsequent shock was almost always effective, and in any event, no patient failed to be reverted by the second 30-J rescue shock. Over the entire follow-up period as long as 17 months, there were 17 deaths. Neither the incidence nor the mode of death was correlated with nonconversion or acceleration. We conclude that low energy cardioversion is effective in treating monomorphic ventricular tachycardia and if unsuccessful, does not prejudice the success of subsequent higher energy therapy.

Original languageEnglish (US)
Pages (from-to)1846-1849
Number of pages4
JournalPACE - Pacing and Clinical Electrophysiology
Volume14
Issue number11 II
StatePublished - 1991
Externally publishedYes

Fingerprint

Electric Countershock
Implantable Defibrillators
Cardiac Arrhythmias
Shock
Ventricular Tachycardia
Equipment and Supplies
Incidence
United States Food and Drug Administration
Clinical Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical efficacy of low energy cardioversion in automatic implantable cardioverter defibrillator patients. / McVeigh, K.; Mower, Morton Maimon; Nisam, S.; Voshage, L.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 14, No. 11 II, 1991, p. 1846-1849.

Research output: Contribution to journalArticle

@article{110c543a84c34ab08c81de145c6a747d,
title = "Clinical efficacy of low energy cardioversion in automatic implantable cardioverter defibrillator patients",
abstract = "The inclusion of low energy cardioversion capability into modern implantable antiarrhythmic devices, although an appealing idea, is nevertheless unproven with regard to its potential benefits. Moreover, since occasional reports have surfaced suggesting that ineffective application of low energy shocks may prejudice subsequent arrhythmia reversion, we examined the effectiveness and risks of this feature in a large series of patients performed as part of a US Food and Drug Administration clinical trial performed under an investigational device exemption. A total of 813 induced monomorphic ventricular tachycardias were studied in 244 patients. We found that many of the arrhythmias could be reverted to sinus rhythm with small amounts of energy. Cardioversion energy was ≤ 6 joules (J) for 84 (53.2{\%}) and ≤ 14 joules in 105 (66.4{\%}) of the 158 patients tested at implant and subsequently remained unchanged through > 4 months follow up. The incidence of noncardioversion, acceleration or both occurred in 12.7{\%}, 5.7{\%}, and 13.1{\%}, respectively on a per patient basis. On a per episode basis, nonconversion occurred in 51 (6.3{\%}) and acceleration in 61 (7.5{\%}) of the 813 inductions. There was no correlation between the occurrence of nonconversions and accelerations. The devices were allowed to recycle in the event the arrhythmia was not reverted. The subsequent shock was almost always effective, and in any event, no patient failed to be reverted by the second 30-J rescue shock. Over the entire follow-up period as long as 17 months, there were 17 deaths. Neither the incidence nor the mode of death was correlated with nonconversion or acceleration. We conclude that low energy cardioversion is effective in treating monomorphic ventricular tachycardia and if unsuccessful, does not prejudice the success of subsequent higher energy therapy.",
author = "K. McVeigh and Mower, {Morton Maimon} and S. Nisam and L. Voshage",
year = "1991",
language = "English (US)",
volume = "14",
pages = "1846--1849",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "11 II",

}

TY - JOUR

T1 - Clinical efficacy of low energy cardioversion in automatic implantable cardioverter defibrillator patients

AU - McVeigh, K.

AU - Mower, Morton Maimon

AU - Nisam, S.

AU - Voshage, L.

PY - 1991

Y1 - 1991

N2 - The inclusion of low energy cardioversion capability into modern implantable antiarrhythmic devices, although an appealing idea, is nevertheless unproven with regard to its potential benefits. Moreover, since occasional reports have surfaced suggesting that ineffective application of low energy shocks may prejudice subsequent arrhythmia reversion, we examined the effectiveness and risks of this feature in a large series of patients performed as part of a US Food and Drug Administration clinical trial performed under an investigational device exemption. A total of 813 induced monomorphic ventricular tachycardias were studied in 244 patients. We found that many of the arrhythmias could be reverted to sinus rhythm with small amounts of energy. Cardioversion energy was ≤ 6 joules (J) for 84 (53.2%) and ≤ 14 joules in 105 (66.4%) of the 158 patients tested at implant and subsequently remained unchanged through > 4 months follow up. The incidence of noncardioversion, acceleration or both occurred in 12.7%, 5.7%, and 13.1%, respectively on a per patient basis. On a per episode basis, nonconversion occurred in 51 (6.3%) and acceleration in 61 (7.5%) of the 813 inductions. There was no correlation between the occurrence of nonconversions and accelerations. The devices were allowed to recycle in the event the arrhythmia was not reverted. The subsequent shock was almost always effective, and in any event, no patient failed to be reverted by the second 30-J rescue shock. Over the entire follow-up period as long as 17 months, there were 17 deaths. Neither the incidence nor the mode of death was correlated with nonconversion or acceleration. We conclude that low energy cardioversion is effective in treating monomorphic ventricular tachycardia and if unsuccessful, does not prejudice the success of subsequent higher energy therapy.

AB - The inclusion of low energy cardioversion capability into modern implantable antiarrhythmic devices, although an appealing idea, is nevertheless unproven with regard to its potential benefits. Moreover, since occasional reports have surfaced suggesting that ineffective application of low energy shocks may prejudice subsequent arrhythmia reversion, we examined the effectiveness and risks of this feature in a large series of patients performed as part of a US Food and Drug Administration clinical trial performed under an investigational device exemption. A total of 813 induced monomorphic ventricular tachycardias were studied in 244 patients. We found that many of the arrhythmias could be reverted to sinus rhythm with small amounts of energy. Cardioversion energy was ≤ 6 joules (J) for 84 (53.2%) and ≤ 14 joules in 105 (66.4%) of the 158 patients tested at implant and subsequently remained unchanged through > 4 months follow up. The incidence of noncardioversion, acceleration or both occurred in 12.7%, 5.7%, and 13.1%, respectively on a per patient basis. On a per episode basis, nonconversion occurred in 51 (6.3%) and acceleration in 61 (7.5%) of the 813 inductions. There was no correlation between the occurrence of nonconversions and accelerations. The devices were allowed to recycle in the event the arrhythmia was not reverted. The subsequent shock was almost always effective, and in any event, no patient failed to be reverted by the second 30-J rescue shock. Over the entire follow-up period as long as 17 months, there were 17 deaths. Neither the incidence nor the mode of death was correlated with nonconversion or acceleration. We conclude that low energy cardioversion is effective in treating monomorphic ventricular tachycardia and if unsuccessful, does not prejudice the success of subsequent higher energy therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025719262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025719262&partnerID=8YFLogxK

M3 - Article

C2 - 1721186

AN - SCOPUS:0025719262

VL - 14

SP - 1846

EP - 1849

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 11 II

ER -